<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01816594</url>
  </required_header>
  <id_info>
    <org_study_id>CBKM120F2203</org_study_id>
    <nct_id>NCT01816594</nct_id>
  </id_info>
  <brief_title>NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer</brief_title>
  <acronym>NeoPHOEBE</acronym>
  <official_title>NeoPHOEBE: Pi3k Inhibition in Her2 OverExpressing Breast cancEr: A Phase II, Randomized, Parallel Cohort, Two Stage, Double-blind, Placebo-controlled Study of Neoadjuvant Trastuzumab Versus Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive, PIK3CA Wild-type and PIK3CA Mutant Primary Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Breast International Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Breast Group (GBG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SOLTI Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, parallel cohort, two stage, double-blind, placebo-controlled study will
      evaluate the oral PI3K inhibitor BKM120 in combination with trastuzumab and paclitaxel in
      HER2-positive primary breast cancer prior to definitive surgery (neo-adjuvant setting).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NeoPHOEBE will evaluate the efficacy (as defined by pCR) of BKM120 (an oral PI3K inhibitor)
      in combination with trastuzumab and paclitaxel in a randomized, placebo-controlled,
      neo-adjuvant study in women diagnosed with primary breast cancer &gt;1.5 cm (by US or MRI) with
      centrally confirmed HER2 overexpression or amplification, and who have not previously
      undergone treatment for invasive breast cancer.

      Prior to the initiation of paclitaxel, there will be a 6-week &quot;biologic window&quot; with
      trastuzumab plus BKM120 or placebo only. The study will be conducted separately in two
      cohorts (PIK3CA mutated and PI3K3CA wild-type) using a two-stage approach. Within each cohort
      patients will be randomized into one of the following treatment arms:

      Arm 1: BKM120 placebo plus trastuzumab for 6 weeks followed by BKM120 placebo plus
      trastuzumab plus weekly paclitaxel for an additional 12 weeks.

      Arm 2: BKM120 plus trastuzumab for 6 weeks followed by BKM120 and trastuzumab plus weekly
      paclitaxel for an additional 12 weeks.

      After completion of study treatment, patients will undergo definitive surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response (pCR) rate</measure>
    <time_frame>week 18</time_frame>
    <description>Rate of pCR (as defined by NSABP criteria - absence of invasive disease in the breast [ypT0]) at the time of surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall objective clinical response rate at the end of the biologic window and prior to surgery</measure>
    <time_frame>baseline, week 6, week 18</time_frame>
    <description>Overall objective clinical response rate = CR + PR rate, measured by US (or MRI) and assessed by world health organization (WHO) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy by other pCR definitions</measure>
    <time_frame>baseline, week 18</time_frame>
    <description>pCR defined as no invasive and non-invasive (DCIS) residuals in breast and lymph nodes (ypT0, ypN0 [GBG definition]); pCR defined as no invasive residuals in breast and lymph nodes (ypT0/Tis, ypN0 [MD Anderson definition]); Percent of patients with remaining DCIS in breast at definitive surgery irrespective of lymph node status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pCR and clinical response by hormone receptor status (Estrogene Receptor (ER)+ versus ER-)</measure>
    <time_frame>baseline, week 18</time_frame>
    <description>pCR and clinical response by hormone receptor status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with node-negative disease at definitive surgery (ypN0)</measure>
    <time_frame>18 weeks</time_frame>
    <description>Percent of patients with node-negative disease at surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of breast conserving surgery</measure>
    <time_frame>18 weeks</time_frame>
    <description>Rate of patients with breast conserving surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>18 weeks</time_frame>
    <description>Frequency and severity of hematological and non-hematological adverse events and laboratory abnormalities</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>HER2-positive, Newly Diagnosed, Primary Breast Cancer, Neoadjuvant Therapy, Trastuzumab</condition>
  <arm_group>
    <arm_group_label>Trastuzumab + BKM120 + paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BKM120 (oral, pan-class I PI3K inhibitor) in combination with trastuzumab and paclitaxel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trastuzumab + BKM120 placebo + paclitaxel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>BKM120 placebo in combination with trastuzumab and paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BKM120</intervention_name>
    <description>Neo-adjuvant BKM120 (oral pan-class I PI3K inhibitor, continuous daily dosing). BKM120 will be administered orally 100 mg/day.</description>
    <arm_group_label>Trastuzumab + BKM120 + paclitaxel</arm_group_label>
    <other_name>Buparsilib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab is a humanized monoclonal antibody directed against the extracellular juxtamembrane domain of the HER2 receptor. Administered 4mg/kg i.v. load followed by 2mg/kg i.v. weekly.</description>
    <arm_group_label>Trastuzumab + BKM120 + paclitaxel</arm_group_label>
    <arm_group_label>Trastuzumab + BKM120 placebo + paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel is a cytotoxic agent with proven antitumor activity in a variety of solid tumors. The antitumor activity of paclitaxel is based on tubulin-binding and stabilization of non-functional microtubule bundles, thereby blocking normal mitotic spindle development and subsequent cell division. Administered weekly 80mg/m2 i.v.</description>
    <arm_group_label>Trastuzumab + BKM120 + paclitaxel</arm_group_label>
    <arm_group_label>Trastuzumab + BKM120 placebo + paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Neoadjuvant BKM120 placebo Administered orally 100 mg/day.</description>
    <arm_group_label>Trastuzumab + BKM120 placebo + paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is a female ≥ 18 years of age

          -  Patient has an ECOG performance status of 0-1

          -  Patient has a unilateral (multifocal or multicentric disease allowed), histologically
             confirmed, newly diagnosed early breast cancer &gt;2cm by clinical examination and/or
             &gt;1.5 cm confirmed by ultrasound or by MRI

          -  Patient has tumor tissue available for central review of ER, HER2 and PI3K status with
             centrally confirmed HER2-positive disease and known PI3KCA mutation status

          -  Patient has adequate bone marrow, renal and liver function

          -  Patient is able to swallow and retain oral medication

        Exclusion Criteria:

          -  Patient has received prior systemic treatment for currently diagnosed disease

          -  Patient has a known contraindications, hypersensitivity or intolerance to trastuzumab,
             paclitaxel or products containing cremophor

          -  Patient has bilateral breast cancer or metastatic disease or inflammatory breast
             cancer

          -  LVEF below 50% as determined by MUGA scan or ECHO

          -  Patient has active cardiac disease or a history of cardiac abnormalities as defined in
             the protocol

          -  Patient has impairment of gastrointestinal (GI) function or GI disease that may
             significantly alter the absorption of BKM120

          -  Patient is currently receiving warfarin or other coumarin derived anti-coagulants

          -  Patient is currently receiving chronic treatment with corticosteroids or another
             immunosuppressive agents (standard premedication for paclitaxel and local applications
             allowed)

          -  Patient is currently receiving treatment with drugs known to be strong inhibitors or
             inducers of CYP3A

          -  Patient has certain scores on an anxiety and depression mood questionnaires

          -  Pregnant or nursing (lactating) women or patients not willing to apply apply highly
             effective contraception as defined in the protocol

          -  Other protocol defined criteria may apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Concord NSW</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Düsseldorf</city>
        <state>Nordrhein Westfalen</state>
        <zip>40235</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Offenbach</city>
        <zip>63069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>4103</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <zip>43204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Germany</country>
    <country>Singapore</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>France</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2013</study_first_submitted>
  <study_first_submitted_qc>March 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2013</study_first_posted>
  <last_update_submitted>September 21, 2015</last_update_submitted>
  <last_update_submitted_qc>September 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2, breast cancer, neoadjuvant, PI3K inhibitor, first line chemotherapy, trastuzumab, GBG, SOLTI, BIG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 11, 2016</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>July 18, 2016</submitted>
    <returned>August 25, 2016</returned>
    <submitted>September 29, 2016</submitted>
    <returned>November 18, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

